PMC:7205724 / 22431-22936 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"788","span":{"begin":172,"end":175},"obj":"Gene"},{"id":"789","span":{"begin":355,"end":358},"obj":"Gene"},{"id":"790","span":{"begin":22,"end":30},"obj":"Species"},{"id":"791","span":{"begin":148,"end":156},"obj":"Species"},{"id":"792","span":{"begin":416,"end":424},"obj":"Species"},{"id":"793","span":{"begin":113,"end":124},"obj":"Chemical"},{"id":"794","span":{"begin":212,"end":223},"obj":"Chemical"},{"id":"795","span":{"begin":289,"end":295},"obj":"Chemical"},{"id":"796","span":{"begin":483,"end":494},"obj":"Chemical"},{"id":"797","span":{"begin":36,"end":44},"obj":"Disease"},{"id":"798","span":{"begin":373,"end":384},"obj":"Disease"},{"id":"799","span":{"begin":462,"end":468},"obj":"Disease"}],"attributes":[{"id":"A788","pred":"tao:has_database_id","subj":"788","obj":"Gene:3569"},{"id":"A789","pred":"tao:has_database_id","subj":"789","obj":"Gene:1401"},{"id":"A790","pred":"tao:has_database_id","subj":"790","obj":"Tax:9606"},{"id":"A791","pred":"tao:has_database_id","subj":"791","obj":"Tax:9606"},{"id":"A792","pred":"tao:has_database_id","subj":"792","obj":"Tax:9606"},{"id":"A793","pred":"tao:has_database_id","subj":"793","obj":"MESH:C502936"},{"id":"A794","pred":"tao:has_database_id","subj":"794","obj":"MESH:C502936"},{"id":"A795","pred":"tao:has_database_id","subj":"795","obj":"MESH:D010100"},{"id":"A796","pred":"tao:has_database_id","subj":"796","obj":"MESH:C502936"},{"id":"A797","pred":"tao:has_database_id","subj":"797","obj":"MESH:C000657245"},{"id":"A798","pred":"tao:has_database_id","subj":"798","obj":"MESH:D008171"},{"id":"A799","pred":"tao:has_database_id","subj":"799","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T164","span":{"begin":329,"end":339},"obj":"Body_part"},{"id":"T165","span":{"begin":373,"end":377},"obj":"Body_part"}],"attributes":[{"id":"A164","pred":"fma_id","subj":"T164","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A165","pred":"fma_id","subj":"T165","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T23","span":{"begin":373,"end":377},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T177","span":{"begin":36,"end":44},"obj":"Disease"}],"attributes":[{"id":"A177","pred":"mondo_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T267","span":{"begin":14,"end":16},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T268","span":{"begin":165,"end":166},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T269","span":{"begin":199,"end":201},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"},{"id":"T270","span":{"begin":373,"end":377},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T271","span":{"begin":373,"end":377},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T171","span":{"begin":212,"end":223},"obj":"Chemical"},{"id":"T172","span":{"begin":289,"end":295},"obj":"Chemical"},{"id":"T173","span":{"begin":483,"end":494},"obj":"Chemical"}],"attributes":[{"id":"A171","pred":"chebi_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A172","pred":"chebi_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"},{"id":"A173","pred":"chebi_id","subj":"T173","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T22","span":{"begin":289,"end":324},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A22","pred":"meddra_id","subj":"T22","obj":"http://purl.bioontology.org/ontology/MEDDRA/10033322"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T102","span":{"begin":265,"end":273},"obj":"http://purl.obolibrary.org/obo/OGMS_0000020"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T110","span":{"begin":289,"end":295},"obj":"Chemical"}],"attributes":[{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T218","span":{"begin":36,"end":44},"obj":"Species"}],"attributes":[{"id":"A218","pred":"ncbi_taxonomy_id","subj":"T218","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T183","span":{"begin":0,"end":147},"obj":"Sentence"},{"id":"T184","span":{"begin":148,"end":366},"obj":"Sentence"},{"id":"T185","span":{"begin":367,"end":425},"obj":"Sentence"},{"id":"T186","span":{"begin":426,"end":505},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T23","span":{"begin":373,"end":377},"obj":"Body_part"}],"attributes":[{"id":"A23","pred":"uberon_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"790","span":{"begin":22,"end":30},"obj":"Species"},{"id":"797","span":{"begin":36,"end":44},"obj":"Disease"},{"id":"793","span":{"begin":113,"end":124},"obj":"Chemical"},{"id":"791","span":{"begin":148,"end":156},"obj":"Species"},{"id":"788","span":{"begin":172,"end":175},"obj":"Gene"},{"id":"794","span":{"begin":212,"end":223},"obj":"Chemical"},{"id":"795","span":{"begin":289,"end":295},"obj":"Chemical"},{"id":"789","span":{"begin":355,"end":358},"obj":"Gene"},{"id":"798","span":{"begin":373,"end":384},"obj":"Disease"},{"id":"792","span":{"begin":416,"end":424},"obj":"Species"},{"id":"799","span":{"begin":462,"end":468},"obj":"Disease"},{"id":"796","span":{"begin":483,"end":494},"obj":"Chemical"}],"attributes":[{"id":"A789","pred":"pubann:denotes","subj":"789","obj":"Gene:1401"},{"id":"A790","pred":"pubann:denotes","subj":"790","obj":"Tax:9606"},{"id":"A788","pred":"pubann:denotes","subj":"788","obj":"Gene:3569"},{"id":"A798","pred":"pubann:denotes","subj":"798","obj":"MESH:D008171"},{"id":"A792","pred":"pubann:denotes","subj":"792","obj":"Tax:9606"},{"id":"A797","pred":"pubann:denotes","subj":"797","obj":"MESH:C000657245"},{"id":"A796","pred":"pubann:denotes","subj":"796","obj":"MESH:C502936"},{"id":"A795","pred":"pubann:denotes","subj":"795","obj":"MESH:D010100"},{"id":"A799","pred":"pubann:denotes","subj":"799","obj":"MESH:D003643"},{"id":"A793","pred":"pubann:denotes","subj":"793","obj":"MESH:C502936"},{"id":"A791","pred":"pubann:denotes","subj":"791","obj":"Tax:9606"},{"id":"A794","pred":"pubann:denotes","subj":"794","obj":"MESH:C502936"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T2161","span":{"begin":172,"end":175},"obj":"Protein"},{"id":"T2205","span":{"begin":355,"end":358},"obj":"Protein"}],"attributes":[{"id":"A2161","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A2162","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A2163","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A2164","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A2165","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A2166","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A2167","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A2168","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A2169","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A2170","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A2171","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A2172","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A2173","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A2174","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A2175","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A2176","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A2177","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A2178","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A2179","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A2180","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A2181","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A2182","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A2183","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A2184","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A2185","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A2186","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A2187","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A2188","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A2189","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A2190","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A2191","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A2192","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A2193","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A2194","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A2195","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A2196","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A2197","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A2198","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A2199","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A2200","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A2201","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A2202","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A2203","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A2204","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/A0S0B0"},{"id":"A2205","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/Q5U0J2"},{"id":"A2206","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/Q07203"},{"id":"A2207","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/Q01687"},{"id":"A2208","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P97315"},{"id":"A2209","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P67967"},{"id":"A2210","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P67966"},{"id":"A2211","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P47875"},{"id":"A2212","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P32965"},{"id":"A2213","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P21291"},{"id":"A2214","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P08462"},{"id":"A2215","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/A8K268"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T21073","span":{"begin":0,"end":2},"obj":"IN"},{"id":"T65150","span":{"begin":3,"end":6},"obj":"DT"},{"id":"T61991","span":{"begin":7,"end":12},"obj":"NN"},{"id":"T18474","span":{"begin":13,"end":14},"obj":"-LRB-"},{"id":"T8341","span":{"begin":14,"end":16},"obj":"CD"},{"id":"T6430","span":{"begin":16,"end":17},"obj":"-RRB-"},{"id":"T29393","span":{"begin":17,"end":18},"obj":"-COMMA-"},{"id":"T77821","span":{"begin":19,"end":21},"obj":"CD"},{"id":"T79215","span":{"begin":22,"end":30},"obj":"NNS"},{"id":"T5404","span":{"begin":31,"end":35},"obj":"IN"},{"id":"T75582","span":{"begin":36,"end":44},"obj":"NN"},{"id":"T89299","span":{"begin":45,"end":50},"obj":"WP-DOLLAR-"},{"id":"T66055","span":{"begin":51,"end":60},"obj":"NN"},{"id":"T80340","span":{"begin":61,"end":64},"obj":"VBD"},{"id":"T3490","span":{"begin":65,"end":71},"obj":"JJ"},{"id":"T44653","span":{"begin":72,"end":74},"obj":"CC"},{"id":"T55941","span":{"begin":75,"end":83},"obj":"JJ"},{"id":"T85453","span":{"begin":84,"end":92},"obj":"VBD"},{"id":"T98598","span":{"begin":93,"end":96},"obj":"CD"},{"id":"T96881","span":{"begin":97,"end":99},"obj":"CC"},{"id":"T24534","span":{"begin":100,"end":103},"obj":"CD"},{"id":"T70238","span":{"begin":104,"end":109},"obj":"NNS"},{"id":"T20616","span":{"begin":110,"end":112},"obj":"IN"},{"id":"T68912","span":{"begin":113,"end":124},"obj":"NNP"},{"id":"T98192","span":{"begin":125,"end":129},"obj":"CC"},{"id":"T20706","span":{"begin":130,"end":138},"obj":"JJ"},{"id":"T58005","span":{"begin":139,"end":146},"obj":"NN"},{"id":"T96625","span":{"begin":148,"end":156},"obj":"NNS"},{"id":"T75572","span":{"begin":157,"end":160},"obj":"WP"},{"id":"T31917","span":{"begin":161,"end":164},"obj":"VBD"},{"id":"T15301","span":{"begin":165,"end":166},"obj":"DT"},{"id":"T24848","span":{"begin":167,"end":171},"obj":"JJ"},{"id":"T84688","span":{"begin":172,"end":175},"obj":"NN"},{"id":"T96963","span":{"begin":176,"end":181},"obj":"NN"},{"id":"T6930","span":{"begin":182,"end":184},"obj":"IN"},{"id":"T90933","span":{"begin":185,"end":189},"obj":"JJR"},{"id":"T81944","span":{"begin":190,"end":194},"obj":"IN"},{"id":"T75581","span":{"begin":195,"end":204},"obj":"NN"},{"id":"T64021","span":{"begin":205,"end":211},"obj":"IN"},{"id":"T9387","span":{"begin":212,"end":223},"obj":"NN"},{"id":"T84664","span":{"begin":224,"end":233},"obj":"NN"},{"id":"T18203","span":{"begin":234,"end":240},"obj":"VBD"},{"id":"T60803","span":{"begin":241,"end":252},"obj":"NN"},{"id":"T44490","span":{"begin":253,"end":255},"obj":"IN"},{"id":"T81402","span":{"begin":256,"end":264},"obj":"JJ"},{"id":"T14228","span":{"begin":265,"end":273},"obj":"NNS"},{"id":"T94537","span":{"begin":274,"end":277},"obj":"CC"},{"id":"T83697","span":{"begin":278,"end":288},"obj":"JJ"},{"id":"T13978","span":{"begin":289,"end":295},"obj":"NN"},{"id":"T35808","span":{"begin":296,"end":306},"obj":"NN"},{"id":"T34900","span":{"begin":307,"end":310},"obj":"CC"},{"id":"T75964","span":{"begin":311,"end":324},"obj":"NN"},{"id":"T84268","span":{"begin":325,"end":328},"obj":"IN"},{"id":"T65028","span":{"begin":329,"end":339},"obj":"NN"},{"id":"T34390","span":{"begin":340,"end":350},"obj":"NN"},{"id":"T96610","span":{"begin":351,"end":354},"obj":"CC"},{"id":"T30755","span":{"begin":355,"end":358},"obj":"NN"},{"id":"T63070","span":{"begin":359,"end":365},"obj":"NNS"},{"id":"T31791","span":{"begin":367,"end":371},"obj":"RB"},{"id":"T31152","span":{"begin":371,"end":372},"obj":"-COMMA-"},{"id":"T79595","span":{"begin":373,"end":377},"obj":"NN"},{"id":"T51431","span":{"begin":378,"end":384},"obj":"NN"},{"id":"T10130","span":{"begin":385,"end":392},"obj":"NN"},{"id":"T31388","span":{"begin":393,"end":396},"obj":"VBD"},{"id":"T1824","span":{"begin":397,"end":405},"obj":"VBN"},{"id":"T60055","span":{"begin":406,"end":408},"obj":"IN"},{"id":"T38598","span":{"begin":409,"end":411},"obj":"CD"},{"id":"T67288","span":{"begin":411,"end":412},"obj":"NN"},{"id":"T48683","span":{"begin":413,"end":415},"obj":"IN"},{"id":"T41529","span":{"begin":416,"end":424},"obj":"NNS"},{"id":"T69670","span":{"begin":426,"end":433},"obj":"CC"},{"id":"T9277","span":{"begin":434,"end":441},"obj":"JJ"},{"id":"T15021","span":{"begin":442,"end":449},"obj":"JJ"},{"id":"T23626","span":{"begin":450,"end":457},"obj":"NNS"},{"id":"T98539","span":{"begin":458,"end":461},"obj":"CC"},{"id":"T65699","span":{"begin":462,"end":468},"obj":"NNS"},{"id":"T50204","span":{"begin":469,"end":477},"obj":"VBD"},{"id":"T20973","span":{"begin":478,"end":482},"obj":"IN"},{"id":"T14012","span":{"begin":483,"end":494},"obj":"NN"},{"id":"T66286","span":{"begin":495,"end":504},"obj":"NN"}],"relations":[{"id":"R75326","pred":"arg1Of","subj":"T85453","obj":"T21073"},{"id":"R27739","pred":"arg2Of","subj":"T61991","obj":"T21073"},{"id":"R82994","pred":"arg1Of","subj":"T61991","obj":"T65150"},{"id":"R48681","pred":"arg1Of","subj":"T61991","obj":"T18474"},{"id":"R80450","pred":"arg2Of","subj":"T8341","obj":"T18474"},{"id":"R99891","pred":"arg3Of","subj":"T6430","obj":"T18474"},{"id":"R98220","pred":"arg1Of","subj":"T85453","obj":"T29393"},{"id":"R79228","pred":"arg1Of","subj":"T79215","obj":"T77821"},{"id":"R3039","pred":"arg1Of","subj":"T79215","obj":"T5404"},{"id":"R31375","pred":"arg2Of","subj":"T75582","obj":"T5404"},{"id":"R14004","pred":"arg1Of","subj":"T66055","obj":"T89299"},{"id":"R84172","pred":"arg2Of","subj":"T75582","obj":"T89299"},{"id":"R52999","pred":"arg1Of","subj":"T66055","obj":"T80340"},{"id":"R29264","pred":"arg2Of","subj":"T44653","obj":"T80340"},{"id":"R90654","pred":"arg1Of","subj":"T66055","obj":"T3490"},{"id":"R25403","pred":"arg1Of","subj":"T3490","obj":"T44653"},{"id":"R81194","pred":"arg2Of","subj":"T55941","obj":"T44653"},{"id":"R78022","pred":"arg1Of","subj":"T66055","obj":"T55941"},{"id":"R74963","pred":"arg1Of","subj":"T79215","obj":"T85453"},{"id":"R42123","pred":"arg2Of","subj":"T70238","obj":"T85453"},{"id":"R67132","pred":"arg1Of","subj":"T70238","obj":"T98598"},{"id":"R74424","pred":"arg1Of","subj":"T98598","obj":"T96881"},{"id":"R53734","pred":"arg2Of","subj":"T24534","obj":"T96881"},{"id":"R5731","pred":"arg1Of","subj":"T70238","obj":"T24534"},{"id":"R65601","pred":"arg1Of","subj":"T70238","obj":"T20616"},{"id":"R56743","pred":"arg2Of","subj":"T98192","obj":"T20616"},{"id":"R89899","pred":"arg1Of","subj":"T68912","obj":"T98192"},{"id":"R61440","pred":"arg2Of","subj":"T58005","obj":"T98192"},{"id":"R97353","pred":"arg1Of","subj":"T58005","obj":"T20706"},{"id":"R37793","pred":"arg1Of","subj":"T96625","obj":"T75572"},{"id":"R91228","pred":"arg1Of","subj":"T96625","obj":"T31917"},{"id":"R53068","pred":"arg2Of","subj":"T96963","obj":"T31917"},{"id":"R75826","pred":"arg1Of","subj":"T96963","obj":"T15301"},{"id":"R53187","pred":"arg1Of","subj":"T96963","obj":"T24848"},{"id":"R88261","pred":"arg1Of","subj":"T96963","obj":"T84688"},{"id":"R96088","pred":"arg1Of","subj":"T96963","obj":"T6930"},{"id":"R5373","pred":"arg2Of","subj":"T90933","obj":"T6930"},{"id":"R57258","pred":"arg1Of","subj":"T90933","obj":"T81944"},{"id":"R94369","pred":"arg2Of","subj":"T75581","obj":"T81944"},{"id":"R45661","pred":"arg1Of","subj":"T90933","obj":"T64021"},{"id":"R79916","pred":"arg2Of","subj":"T84664","obj":"T64021"},{"id":"R78642","pred":"arg1Of","subj":"T84664","obj":"T9387"},{"id":"R8185","pred":"arg1Of","subj":"T96625","obj":"T18203"},{"id":"R51850","pred":"arg2Of","subj":"T94537","obj":"T18203"},{"id":"R12091","pred":"arg1Of","subj":"T60803","obj":"T44490"},{"id":"R66809","pred":"arg2Of","subj":"T14228","obj":"T44490"},{"id":"R61551","pred":"arg1Of","subj":"T14228","obj":"T81402"},{"id":"R5554","pred":"arg1Of","subj":"T60803","obj":"T94537"},{"id":"R21619","pred":"arg2Of","subj":"T34900","obj":"T94537"},{"id":"R92393","pred":"arg1Of","subj":"T35808","obj":"T83697"},{"id":"R24887","pred":"arg1Of","subj":"T35808","obj":"T13978"},{"id":"R90774","pred":"arg1Of","subj":"T35808","obj":"T34900"},{"id":"R67692","pred":"arg2Of","subj":"T75964","obj":"T34900"},{"id":"R62752","pred":"arg1Of","subj":"T34900","obj":"T84268"},{"id":"R8244","pred":"arg2Of","subj":"T63070","obj":"T84268"},{"id":"R10896","pred":"arg1Of","subj":"T63070","obj":"T65028"},{"id":"R57903","pred":"arg1Of","subj":"T63070","obj":"T34390"},{"id":"R97168","pred":"arg1Of","subj":"T34390","obj":"T96610"},{"id":"R13130","pred":"arg2Of","subj":"T30755","obj":"T96610"},{"id":"R88299","pred":"arg1Of","subj":"T63070","obj":"T30755"},{"id":"R81985","pred":"arg1Of","subj":"T1824","obj":"T31791"},{"id":"R90910","pred":"arg1Of","subj":"T1824","obj":"T31152"},{"id":"R99138","pred":"arg1Of","subj":"T10130","obj":"T79595"},{"id":"R9904","pred":"arg1Of","subj":"T10130","obj":"T51431"},{"id":"R90450","pred":"arg1Of","subj":"T10130","obj":"T31388"},{"id":"R27294","pred":"arg2Of","subj":"T1824","obj":"T31388"},{"id":"R44975","pred":"arg2Of","subj":"T10130","obj":"T1824"},{"id":"R49421","pred":"arg1Of","subj":"T1824","obj":"T60055"},{"id":"R89954","pred":"arg2Of","subj":"T67288","obj":"T60055"},{"id":"R85705","pred":"arg1Of","subj":"T67288","obj":"T38598"},{"id":"R91084","pred":"arg1Of","subj":"T67288","obj":"T48683"},{"id":"R76104","pred":"arg2Of","subj":"T41529","obj":"T48683"},{"id":"R22449","pred":"arg1Of","subj":"T98539","obj":"T69670"},{"id":"R42879","pred":"arg1Of","subj":"T98539","obj":"T9277"},{"id":"R85183","pred":"arg1Of","subj":"T98539","obj":"T15021"},{"id":"R27191","pred":"arg1Of","subj":"T23626","obj":"T98539"},{"id":"R64318","pred":"arg2Of","subj":"T65699","obj":"T98539"},{"id":"R37231","pred":"arg1Of","subj":"T98539","obj":"T50204"},{"id":"R56159","pred":"arg1Of","subj":"T50204","obj":"T20973"},{"id":"R79941","pred":"arg2Of","subj":"T66286","obj":"T20973"},{"id":"R50965","pred":"arg1Of","subj":"T66286","obj":"T14012"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-PD-MAT","denotations":[{"id":"T7","span":{"begin":373,"end":377},"obj":"http://purl.obolibrary.org/obo/MAT_0000135"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T164","span":{"begin":329,"end":339},"obj":"Body_part"},{"id":"T165","span":{"begin":373,"end":377},"obj":"Body_part"}],"attributes":[{"id":"A164","pred":"fma_id","subj":"T164","obj":"http://purl.org/sig/ont/fma/fma62863"},{"id":"A165","pred":"fma_id","subj":"T165","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T167","span":{"begin":36,"end":44},"obj":"Disease"}],"attributes":[{"id":"A167","pred":"mondo_id","subj":"T167","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}

{"project":"LitCovid-sentences","denotations":[{"id":"T183","span":{"begin":0,"end":147},"obj":"Sentence"},{"id":"T184","span":{"begin":148,"end":366},"obj":"Sentence"},{"id":"T185","span":{"begin":367,"end":425},"obj":"Sentence"},{"id":"T186","span":{"begin":426,"end":505},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In the study [27], 21 patients with COVID-19 whose condition was severe or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lung lesion opacity was absorbed in 90% of patients. Neither serious adverse effects nor deaths occurred with tocilizumab treatment."}